Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
329
CURRENT SCENARIO OF TYPE II DIABETES MELLITUS
Dinesh Kawade*, Nidhi Dhote, Payal Bahadurkar, Payal Hiradewe and
Nikhil Shahu
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road,
Nagpur-440016, MS, India.
ABSTRACT
Diabetes, a significant way of life issue, has become a worldwide
weight, and the pervasiveness rates are increasing steeply in creating
economies. Quick financial change with urbanization and
industrialization are the fundamental driver for the worldwide diabetes
pestilence. Among creating economies, the most noteworthy increment
in number of individuals with diabetes is in China followed by India.
In India, the plague of diabetes proceed to increment and is
encountering a move in diabetes pervasiveness from urban to rustic
regions, the well-off to the less special and from more seasoned to
more youthful individuals. Diabetes is a dynamic issue prompting
entanglements, which are extensively isolated into little vessel or
microvascular malady and huge vessel or macrovascular illness. Microvascular complexities
influence the inward piece of the eye-the retina known as diabetic retinopathy, the kidney
named as diabetic nephropathy and the fringe nerves named as diabetic neuropathy. The
macrovascular inconveniences influence the heart, the cerebrum and the fringe corridors
named as cardiovascular sickness, cerebrovascular ailment and fringe vascular ailment,
separately. India have the most extreme increment during the most recent couple of years.
Type 2 diabetes mellitus is the commonest type of diabetes.
KEYWORDS: Diabetes mellitus, disease perceptions, explanatory models, illness narratives,
type 2 diabetes.
INTRODUCTION
Type 2 diabetes is the most common type of diabetes. It is a chronic condition in which blood
glucose (sugar) can no longer be regulated. There are two reasons for this. First, the cells of
World Journal of Pharmaceutical Research SJIF Impact Factor 8.084
Volume 9, Issue 5, 329-349. Review Article ISSN 2277– 7105
Article Received on
27 February. 2020,
Revised on 17 March 2020,
Accepted on 07 April 2020
DOI: 10.20959/wjpr20205-17259
*Corresponding Author
Dinesh Kawade
Priyadarshini J. L. College
of Pharmacy, Electronic
Zone Building, MIDC,
Hingna Road, Nagpur-
440016, MS, India.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
330
the body become resistant to insulin (insulin resistant). Insulin works like a key to let glucose
(blood sugar) move out of the blood and into the cells where it is used as fuel for energy.
When the cells become insulin resistant, moving sugar into the cells requires more and more
insulin, and too much sugar stays in the blood. Over time, if the cells require more and more
insulin, the pancreas can't make enough insulin to keep up and begins to fail.
Epidemiology
The prevalence of diabetes is rapidly rising all over the globe at an alarming rate. Over the
past 30 yr, the status of diabetes has changed from being considered as a mild disorder of the
elderly to one of the major causes of morbidity and mortality affecting the youth and middle
aged people. It is important to note that the rise in prevalence is seen in all six inhabited
continents of the globe. Although there is an increase in the prevalence of type 1 diabetes
also, the major driver of the epidemic is the more common form of diabetes, namely type 2
diabetes, which accounts for more than 90 per cent of all diabetes cases. Nowhere is the
diabetes epidemic more pronounced than in India as the World Health Organization (WHO)
reports show that 32 million people had diabetes in the year 2000. The International Diabetes
Federation (IDF) estimates the total number of diabetic subjects to be around 40.9 million in
India and this is further set to rise to 69.9 million by the year 2025 (Fig.1).
Etiology
Type 2 diabetes is a condition in which cells cannot use blood sugar (glucose) efficiently for
energy. This happens when the cells become insensitive to insulin and the
blood sugar gradually gets too high. There are two types of diabetes mellitus, type 1 and type
2. In type 2, the pancreas still makes insulin, but the cells cannot use it very efficiently.
In type 1 diabetes, the pancreas cannot make insulin due to auto-immune destruction of the
insulin-producing beta cells.
Type 2 can be caused by
Being overweight
Eating a lot of foods or drinks with sugar and simple carbohydrates
Artificial sweeteners (sugar free sodas, sugar free foods) intake
Lack of activity (sedentary behavior)
Lack of exercise
Stress and stress hormones
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
331
Genetics
Risk factors include
Having family members with diabetes
Being overweight
Being sedentary including watching more than 2 hours of TV per day
Drinking soda
Consuming too much sugar and processed food
Often there are no specific symptoms of the condition and it goes undiagnosed until routine
blood tests are ordered. A blood sugar level more than 125 when fasting or more than 200
randomly is a diagnosis for diabetes. Treatment is with diet and lifestyle changes that include
eating less sugary foods and fewer foods that are high in simple carbohydrates (sugar, bread,
and pasta). Sometimes a person will need to take drugs, for xample, metformin (Glucophage).
People with both types of diabetes need to monitor their blood sugar levels often to avoid
high (hyperglycemia) and low blood sugar levels (hypoglycemia). Complications include
heart and kidney disease, neuropathy, sexual and/or urinary problems, foot problems, and eye
problems.
This health condition can be prevented by following a low-glycemic load diet, staying
physically active, and getting regular medical screenings. The prognosis for a person with
this health condition is estimated to be a life expectancy of 10 years less than a person
without diabetes. However, good blood sugar control and taking steps to prevent
complications are shortening this gap, and people with the condition are living longer than
ever before. It can be reversed with diligent attention to changing lifestyle behaviors.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
332
Sign and Symptoms
This type of diabetes develops gradually, over years, so the signs and symptoms can seem
subtle, and you might think it is something you "just have to live with." If you are overweight
or obese, this is the major symptom, but not everyone will be overweight. In fact, weight
loss can be a symptom.
Other symptoms and signs include:
1. Fatigue
2. Frequent urination
3. Excess thirst
4. Blurry or cloudy vision
5. Wounds that won't heal
6. Tingling or numbness in the feet
7. Erectile dysfunction (ED)
8. Dark skin under the armpits and around the groin
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
333
Signs and symptoms of low blood sugar (hypoglycemia)
Type 2 diabetes is a condition of blood sugar dysregulation. In general blood sugar is too
high, but it also can be too low. This can happen if you take your diabetes medications then
skip a meal. Blood sugar also can rise very quickly after a high glycemic index meal, and
then fall a few hours later, plummeting into hypoglycemia (low blood sugar). The signs
and symptoms of hypoglycemia can include
i Feeling dizzy or light-headed
ii Difficulty concentrating or making decisions
iii Feeling sweaty or clammy
iv Vision changes, like blurring or narrowing of the visual field
v Feeling physically weak
vi Feeling sleepy
vii Feeling irritable
Signs and symptoms of high blood sugar (hyperglycemia)
Hyperglycemia, or high blood sugar, is common in type 2 diabetes. Its signs and symptoms
can be either acute (short in duration) or chronic (last over a long period of time).
Acute symptoms include
i Feeling tired
ii Feeling vision is blurry or foggy
iii Frequent urination
iv Feeling very thirsty
Chronic signs and symptoms can include
i Darkening skin under armpits, neck, thighs
ii Fungal infections on the skin like ringworm or toenail fungus
iii Weight gain
iv Difficulty with sexual function
v Numbness, tingling, or burning sensations in the feet
Risk factors for type 2 diabetes mellitus
Risk factors for type 2 diabetes are:
Age (being over age 45)
A family history of diabetes
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
334
Being of a race or ethnic group with a genetic predisposition for this type of diabetes
Being overweight
Having had prediabetes or gestational diabetes
Having other metabolic syndrome conditions such as high blood pressure, low HDL or
"good" cholesterol, or high triglycerides.
Pathophysiology of type 2 diabetes mellitus
Type 2 diabetes mellitus is a heterogeneous disorder with varying prevalence among different
ethnic groups. In the United States the populations most affected are native Americans,
particularly in the desert Southwest, Hispanic-Americans, and Asian-Americans. The
pathophysiology of type 2 diabetes mellitus is characterized by peripheral insulin resistance,
impaired regulation of hepatic glucose production, and declining β-cell function, eventually
leading to β -cell failure.The primary events are believed to be an initial deficit in insulin
secretion and, in many patients, relative insulin deficiency in association with peripheral
insulin resistance.
The β-cell
β-Cell dysfunction is initially characterized by an impairment in the first phase of insulin
secretion during glucose stimulation and may antedate the onset of glucose intolerance in
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
335
type 2 diabetes .Initiation of the insulin response depends upon the transmembranous
transport of glucose and coupling of glucose to the glucose sensor. The glucose/glucose
sensor complex then induces an increase in glucokinase by stabilizing the protein and
impairing its degradation. The induction of glucokinase serves as the first step in linking
intermediary metabolism with the insulin secretory apparatus. Glucose transport inβ -cells of
type 2 diabetes patients appears to be greatly reduced, thus shifting the control point for
insulin secretion from glucokinase to the glucose transport system. This defect is improved
by the sulfonylureas. Later in the course of the disease, the second phase release of newly
synthesized insulin is impaired, an effect that can be reversed, in part at least in some
patients, by restoring strict control of glycemia. This secondary phenomenon, termed
desensitization or β-cell glucotoxicity, is the result of a paradoxical inhibitory effect of
glucose upon insulin release and may be attributable to the accumulation of glycogen within
the β-cell as a result of sustained hyperglycemia. Other candidates that have been proposed
are sorbital accumulation in the β-cell or the nonenzymatic glycation of β -cell proteins.
Other defects in β-cell function in type 2 diabetes mellitus include defective glucose
potentiation in response to nonglucose insulin secretagogues, asynchronous insulin release,
and a decreased conversion of proinsulin to insulin. An impairment in first phase insulin
secretion may serve as a marker of risk for type 2 diabetes mellitus in family members of
individuals with type 2 diabetes mellitus and may be seen in patients with prior gestational
diabetes. However, impaired first phase insulin secretion alone will not cause impaired
glucose tolerance. Autoimmune destruction of pancreatic β-cells may be a factor in a small
subset of type 2 diabetic patients and has been termed the syndrome of latent autoimmune
diabetes in adults. This group may represent as many as 10% of Scandinavian patients with
type 2 diabetes and has been identified in the recent United Kingdom study, but has not been
well characterized in other populations. Glucokinase is absent within the β-cell in some
families with maturity-onset diabetes of young. However, deficiencies of glucokinase have
not been found in other forms of type 2 diabetes. In summary, the delay in the first phase of
insulin secretion, although of some diagnostic import, does not appear to act independently in
the pathogenesis of type 2 diabetes. In some early-onset patients with type 2 diabetes
(perhaps as many as 20%), there may be a deficiency in insulin secretion that may or may not
be due to autoimmune destruction of the β-cell and is not due to a deficiency in the
glucokinase gene. In the great majority of patients with type 2 diabetes (±80%), the delay in
immediate insulin response is accompanied by a secondary hypersecretory phase of insulin
release as a result of either an inherited or acquired defect within the β-cell or a compensatory
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
336
response to peripheral insulin resistance. Over a prolonged period of time, perhaps years,
insulin secretion gradually declines, possibly as a result of intraislet accumulation of glucose
intermediary metabolites. In view of the decline in β-cell mass, sulfonylureas appear to serve
a diminishing role in the long term management of type 2 diabetes. Unanswered is whether
amelioration of insulin resistance with earlier detection or newer insulin-sensitizing drugs
will retard the progression of β-cell failure, obviating or delaying the need for insulin therapy.
Insulin resistance
Emanating from the prismatic demonstration by Yalow and Berson of the presence of
hyperinsulinism in type 2 diabetes, insulin resistance has been considered to play an integral
role in the pathogenesis of the disease. Recent critical reviews, however, have questioned the
primacy, specificity, and contribution of insulin resistance to the disease state. As chronic
hyperinsulinemia inhibits both insulin secretion and action, and hyperglycemia can impair
both the insulin secretory response to glucose as well as cellular insulin sensitivity, the
precise relation between glucose and insulin level as a surrogate measure of insulin resistance
has been questioned. Lean type 2 diabetic patients over 65 yr of age have been found to be as
insulin sensitive as their age-matched nondiabetic controls. Moreover, in the majority of type
2 diabetic patients who are insulin resistant, obesity is almost invariably present. As obesity
or an increase in intraabdominal adipose tissue is associated with insulin resistance in the
absence of diabetes, it is believed by some that insulin resistance in type 2 diabetes is entirely
due to the coexistence of increased adiposity. Additionally, insulin resistance is found in
hypertension, hyperlipidemia, and ischemic heart disease, entities commonly found in
association with diabetes, again raising the question as to whether insulin resistance results
from different pathogenetic disease processes or is unique to the presence of type 2 diabetes.
Prospective studies have demonstrated the presence of either insulin deficiency or insulin
resistance before the onset of type 2 diabetes. Two studies have reported the presence of
insulin resistance in nondiabetic relatives of diabetic patients at a time when their glucose
tolerance was still normal. In addition, first degree relatives of patients with type 2 diabetes
have been found to have impaired insulin action upon skeletal muscle glycogen synthesis due
to both decreased stimulation of tyrosine kinase activity of the insulin receptor and reduced
glycogen synthase activity. Other studies in this high risk group have failed to demonstrate
insulin resistance, and in the same group, impaired early phase insulin release and loss of
normal oscillatory pattern of insulin release have been described. Based upon these divergent
studies, it is still impossible to dissociate insulin resistance from insulin deficiency in the
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
337
pathogenesis of type 2 diabetes. However, both entities unequivocally contribute to the fully
established disease.
The liver
The ability of insulin to suppress hepatic glucose production both in the fasting state and
postprandially is normal in first degree relatives of type 2 diabetic patients. It is the increase
in the rate of postprandial glucose production that heralds the evolution of IGT. Eventually,
both fasting and postprandial glucose production increase as type 2 diabetes progresses.
Hepatic insulin resistance is characterized by a marked decrease in glucokinase activity and a
catalytic increased conversion of substrates to glucose despite the presence of insulin. Thus,
the liver in type 2 diabetes is programmed to both overproduce and underuse glucose. The
elevated free fatty acid levels found in type 2 diabetes may also play a role in increased
hepatic glucose production. In addition, recent evidence suggests an important role for the
kidney in glucose production via gluconeogenesis, which is unrestrained in the presence of
type 2 diabetes.
Clinical Manifestations
More thirst - When sugar builds up in your blood, your kidneys work overtime to get rid of it.
This pulls fluids from your tissues and makes you dehydrated, so you feel thirsty.
More hunger - Because diabetes can stop glucose from getting to your cells, you feel
hungry, even after you’ve eaten.
Peeing often - You’ll pee more because your kidneys are working to get rid of extra sugar in
your system.
Dry mouth - Dehydration and peeing a lot can drain moisture from your mouth as well.
Weight loss without trying - When you lose sugar from peeing a lot, you lose calories, too.
You might lose weight even though you’re eating as usual.
Fatigue - When your body can’t use energy from food, you could feel weak
and tired. Dehydration can make you feel this way, too.
Blurry vision - High blood sugar can make you have trouble focusing.
Headaches - High blood sugar levels can cause your head to hurt.
Loss of consciousness - After you exercise, skip a meal, or take too much medication, your
blood sugar could go too low, and you could pass out.
Infections or sores that don’t heal - High blood sugar can slow blood flow and make it
harder for your body to heal.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
338
Tingling hands and feet - Type 2 diabetes can affect nerves in your hands and feet.
Red, swollen, tender gums - You might be more likely to get infections in your gums and the
bones that hold your teeth in place. Your gums may get infected or pull away from your teeth.
Your teeth might become loose.
Complications of Type 2 Diabetes
It’s important to get your blood sugar under control to avoid these serious conditions:
Hypoglycemia - If your blood sugar falls below 70 milligrams per deciliter (mg/dL), it can
lead to accidents, coma, and death.
Hyperglycemia - Blood sugar that goes above 180 to 200 mg/dL can give you heart, nerve,
kidney, and vision problems. Over the long term, it also can cause coma and death.
Over time, people with type 2 diabetes may have other health problems:
Diabetic ketoacidosis - When you don’t have enough insulin in your system, your blood
sugar rises, and your body breaks down fat for energy. Toxic acids called ketones build up and
spill into your urine. It can cause coma and death if you don’t treat it.
Heart and blood vessel diseases - People with diabetes are more likely to have conditions
like high blood pressure and high cholesterol, which play a role in heart disease. Also, high
blood sugar can damage your blood vessels and the nerves that control your heart.
High blood pressure - Diabetes doubles your risk of high blood pressure, which makes you
more likely to have heart disease or stroke.
Nerve damage (diabetic neuropathy) - This can cause tingling and numbness, most often in
your feet and legs. But it can also affect your digestive system, urinary tract, blood vessels, and
heart.
Eye damage - Diabetes can cause:
Glaucoma, a buildup of pressure in your eyes
Cataracts, a cloudiness of your lens
Retinopathy, which is damage to the blood vessels in your eyes
Kidney disease -Your kidneys may have to work harder to filter out the extra sugar, along
with all the other waste products in your blood.
Hearing problems - Doctors aren’t sure why this happens, but they think high blood sugar
levels damage the small blood vessels in your ears.
Skin problems - Diabetes can cause:
Infections - You’re more likely to get bacterial and fungal infections.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
339
Itching - Causes include infections, dry skin, and poor circulation. You might notice it on your
lower legs.
Acanthosis nigricans - These velvety darker areas can appear on your neck, armpits, groin,
hands, elbows, and knees.
Diabetic dermopathy - Changes to small blood vessels that look like red or brown scaly
patches. They often show up on your feet and the fronts of your legs.
Necrobiosis lipoidica diabeticorum - This rare condition also affects your blood vessels. It
starts as a dull, red, raised area, but winds up as a shiny scar with a violet border. Your skin
could itch or crack open. Women are more likely to get this than men.
Allergic reactions - You could get these in response to insulin or another diabetes medication.
Diabetic blisters(bullosis diabeticorum) - These sores look like burn blisters and can show
up on the backs of your fingers, hands, toes, feet, and sometimes legs or forearms.
Disseminated granuloma annulare - You might get red, brown, or skin-colored rings or arc-
shaped raised areas on your fingers, ears, or trunk.
Type 2 Diabetes in Children
Type 2 was once called adult-onset diabetes because it was rare in children and teens. But it has
become more common since the mid-1990s, in large part because more young people are
overweight or obese, a risk factor for the disease.
Children are also at higher risk of type 2 diabetes if they don’t get enough exercise or if they have
a close relative with the condition. African American, Hispanic, Native American, Alaska Native,
Asian American, and Pacific Islander children are more likely to get it.
Type 2 Diabetes in Older Adults
Your risk of type 2 diabetes goes up as you age because your body can become resistant to
insulin and your pancreas might not work as well as it used to.
Diabetes is more likely to cause complications in people 65 and older, especially heart
attacks, eye problems, loss of a leg (amputation), and kidney disease.
Screening
Persons older than 40 years of age should be screened annually. More frequent screening is
recommended for individuals with additional risk factors for diabetes.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
340
Certain races/ethnicities (Native American, African American, Hispanics or Asian
American, Pacific Islander),
Overweight or obese persons with a BMI greater than or equal to 25 kg/m2 or 23 kg/m2
in Asian Americans,
First-degree relative with diabetes mellitus
History of cardiovascular disease, hypertension
Low HDL-cholesterol or hypertriglyceridemia,
Women with polycystic ovarian syndrome
Physical inactivity
Conditions associated with insulin resistance, for example, Acanthosis nigricans.
Women diagnosed with gestational diabetes mellitus (GDM) should have lifelong testing at
least every three years. For all other patients, testing should begin at age 45 years, and if
results are normal, patients should be tested at a minimum of every 3-years.
The same tests are used to both screen for and diagnose diabetes. These tests also detect
individuals with prediabetes.
Diagnosis
Diabetes can be diagnosed either by the hemoglobin A1C criteria or plasma glucose
concentration (fasting or 2-hour plasma glucose).
Fasting Plasma Glucose (FPG)
A blood sample is taken after an 8 hour overnight fast. As per ADA, fasting plasma glucose
(FPG) level of more than 126 mg/dL (7.0 mm/L) is consistent with the diagnosis.
Two-Hour Oral Glucose Tolerance Test (OGTT)
In this test, the plasma glucose level is measured before and 2 hours after the ingestion of 75
gm of glucose. DM is diagnosed if the plasma glucose (PG) level in the 2-hour sample is
more than 200 mg/dL (11.1mmol/L). It is also a standard test but is inconvenient and more
costly than FPG and has major variability issues. Patients need to consume a diet with at least
150 g per day of carbohydrate for 3 to 5 days and not take any medications that can impact
glucose tolerance, such as steroids and thiazide diuretics.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
341
Glycated Hemoglobin (Hb) A1C
This test gives an average of blood glucose over the last 2 to 3 months. Patients with an Hb
A1C greater than 6.5% (48mmol/mol) are diagnosed as having DM. Hb A1C is a convenient,
rapid, standardized test and shows less variation due to pre-analytical variables. It is not much
affected by acute illness or stress.
Hb A1C is costly and has many issues, as discussed below, including lower sensitivity. Hb
A1C should be measured using the National Glycohemoglobin Standardization Program
(NGSP) certified method standardized to Diabetes Control and Complications Trial (DCCT)
assay. It is affected by numerous conditions such as sickle cell disease, pregnancy,
hemodialysis, blood loss or transfusion, or erythropoietin therapy. It has not been well
validated in non-Caucasian populations.
Anemia due to deficiency of iron or vitamin B12 leads to spurious elevation of Hb A1C,
limiting its use in countries with a high prevalence of anemia. Also, in children and the
elderly, the relation between Hb A1C and FPG is suboptimal.
For all of the above tests, if the person is asymptomatic, testing should be repeated later to
make a diagnosis of diabetes mellitus.
In patients with classic symptoms of hyperglycemia (increased thirst, increased hunger,
increased urination), random plasma glucose more than 200 mg/dL is also sufficient to
diagnose DM.
FPG, 2-hour PG during 75-g GTT, and Hb A1C are equally appropriate for the diagnosis of
DM. There is no concordance between the results of these tests.
Differential Diagnosis
The list of differential diagnosis of diabetes mellitus consists of various conditions that would
exhibit similar signs and symptoms:
Drug-induced signs and symptoms due to corticosteroids, neuroleptics, pentamidine, etc
Genetic aberrations in beta-cell function and insulin action
Metabolic syndrome (syndrome X)
Infection
Endocrinopathies such as acromegaly, Cushing disease, pheochromocytoma,
hypothyroidism, etc
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
342
Complications of iron overload (hemochromatosis)
Conditions affecting the exocrine part of the pancreas such as pancreatitis, cystic fibrosis,
etc.
Prognosis
DM is associated with increased ASCVD, and treating BP, statin use, regular exercise, and
smoking cessation are of great importance in ameliorating risk. The overall excess mortality
in those with T2DM is around 15% higher but varies widely. The prevalence of vision-
threatening diabetic retinopathy in the United States is about 4.4% among adults with
diabetes, while it is 1% for end-stage renal disease. Today, with pharmacotherapy for
hyperglycemia, as well as lowering LDL cholesterol and managing BP with ACE/ARB
therapy, with other antihypertensive medications and aspirin in secondary prevention,
vascular complications can be managed adequately resulting in a reduction in morbidity and
mortality.
Treatment of T2DM
Non-pharmacologic Treatment
It is well-established that lifestyle plays a crucial role in prevention and treatment of T2DM.
The ADA endorses the education of diabetes self-management. This education can help the
patient to obtain necessary knowledge and skills for self-care, manage hyperglycemia and
possible hypoglycemia, and make lifestyle changes. Primary non-pharmacological
interventions mainly include appropriate nutritional diet, regular physical exercise and
smoking cessation. Diet and regular exercise from moderate to intense can improve glucose
levels in patients with T2DM and those at risk for developing obese and T2DM. Lifestyle
intervention is a proven strategy for reducing diabetes incidence. Nevertheless, the
intervention is considered effective only in the short term but is difficult to adhere to in the
long run, thus limiting its effectiveness.
Anti-diabetes pharmacotherapy
The ultimate goal for the pharmacotherapy is to modify disease progression in a manner
preventing pathophysiological decline towards β-cell dysfunction and long-term
complications associated with hyperglycemia. People should be aware that all anti-diabetic
drugs except insulin require some degree of residual pancreatic β-cells to perform function. A
single anti-hyperglycemic drug often suffices initially, but a second drug with a different
mechanism of action usually is required with the disease progression. In advanced T2DM,
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
343
insulin intervention may be necessary. For convenience, oral agents are typically the first
choice for the treatment of T2DM but oral delivery bears some drawbacks such as frequent
dosing, short half life, and low bioavailability. We outline major anti-diabetic drugs for their
efficacy, safety and mechanisms of action in the following pages. It is important for both
clinicians and patients to obtain a broad understanding of each class of oral agents so as to
optimize diabetic control. In addition, despite the availability of many oral anti-diabetic
agents, therapeutic efficacy in some of them is offset by side effects such as weight gain and
hypoglycemia. Furthermore, treatment with glucose-lowering agents is generally
characterized by loss of efficiency over time, due to progressive β-cell dysfunction. Thereby,
there is an unceasing requirement for adjustment including agent dose, and/or agent type or a
combination of different agents in all stages of the disease.
Metformin: Metformin is one of the oldest but the safest agents used in the treatment of
T2DM. Metformin is the first choice of recommended therapy for T2DM according to the
International Diabetes Federation Global Guideline for T2DM, in agreement with similar
guidelines from the ADA, as well as the European Association for the Study of Diabetes
(EASD). Metformin exerts its effects primarily by reducing hepatic glucose output through
inhibition of gluconeogenesis and has a comparatively lesser effect increasing insulin
sensitivity. Hence, unlike insulin or sulfonylureas, metformin is primarily an
antihyperglycemic agent, rather than a hypoglycemic agent. As a result, metformin does not
cause hypoglycemia. In addition, it does not cause weight gain due to its anorexic effect.
Weight gain can worsen the course of the disease in the long run [. Metformin also modestly
reduces plasma triglyceride concentrations resulting from decreased production of very low
density lipoprotein and has favorable effects on a number of cardiovascular risk factors such
as lipids, body weight, blood pressure and platelet function. Therefore, metaformin is
particularly suitable for T2DM obese patients with cardiovascular diseases. Another
advantage of metformin is the reduction of mortality, as documented in the UKPDS. The
most common reported adverse reaction to metformin therapy is gastrointestinal upset
including nausea, vomiting, anorexia and diarrhea. Thus, metformin should be started at a
low dose at first (500 mg PO bid).
Sulfonylureas: Sulfonylurea binds to the sulfonylurea receptor on the surface of the β-cells
and inhibits potassium efflux, thus depolarizing the β-cells and facilitating insulin release.
Because sulfonylurea acts by stimulating insulin release from β-cells, patients without a
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
344
sufficient number of β-cells, such as those with later stages of T2DM, do not respond to the
medication. An advantage of sulfonylureas is its low cost to patients. Its disadvantage is that
sulfonylurea treatment carries a risk of hypoglycemia, especially in elderly patients. In
addition, the drug promotes weight gain. Many patients can increase more than 2 kg after
initiative medication. Furthermore, sulfonylureas are associated with a higher cardiovascular
risk than metformin likely due to impairment of endothelial function with increased risk for
ischemic complications.
GLP1 receptor agonists and DPP-4 inhibitors: Glucagon-like peptide 1 (GLP-1) is a 30-
amino-acid peptide. It is an incretin hormone produced by ileum and colon, and released into
the bloodstream. GLP-1 is released in response to meal ingestion and blood glucose
concentration in a harmonized fashion for hormone release. GLP-1 also exerts an anti-
diabetic effect by delaying gastric emptying, suppressing glucagon release and increasing
glucose-stimulated insulin release. The resulting effect of GLP-1 is to curb postprandial
hyperglycemia, but its half-life after secretion into the blood is very short. Thus, two
strategies are used to overcome this problem.
A) Incretin mimetic such as liraglutide, approved by FDA in 2010, is a long acting GLP-1
degradation enzyme analogue for treatment of T2DM. It has a long half-life of 14 h and is
resistant to dipeptidyl peptidase-4 (DPP-4) degradation.
B). GLP-1 degradation enzyme inhibitors like DPP-4 is the newest class of oral agents for the
treatment of T2DM. DPP-4 inhibitors such as vildagliptin, sitagliptin, saxagliptin, linagliptin
and alogliptin inhibit the enzymatic degradation of GLP-1. As a consequence, GLP-1
concentration increases, leading to decreased postprandial glucose level. DPP-4 inhibitors
and incretin mimetics do not carry a risk of hypoglycemia, as these drugs seldom alter insulin
secretion levels during fasting state. Another major advantage of the DPP-4 inhibitors is to
retain body weight when the patient is mal-nourished or under weight. DPP-4 inhibitors are
approved for both monotherapy and co-deliver with metformin and thiazolidinediones. DPP-
4 inhibitors have gastrointestinal side effects and may cause urticaria. Moreover, cost of
DPP-4 inhibitors is high, a major limiting factor for their clinical use.
Thiazolidinediones: Thiazolidinediones (TZDs) including rosiglitazone and pioglitazone are
drugs acting as insulin sensitizers. The effects of TZDs are mediated through peroxisome
proliferatoractivated receptor-γ (PPAR-γ). PPAR- receptors are mainly located in the
adipocytes, and also distributed in skeletal muscle, liver and the pancreatic β-cells. The TZD-
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
345
PPAR complex acts on response elements in promoter regions to affect the transcription of
many genes. They may stimulate production of proteins that increase insulin sensitivity and
block transcription of proteins responsible for insulin resistance or inflammation. In addition
to glucose-lowering effects, pioglitazone may also improve lipid profiles, possibly due to its
partial PPAR-α activity. Pioglitazone has a very low risk of hypoglycemia in monotherapy.
SGLT-2 inhibitors: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are another new
class of anti-diabetic drug with an insulinindependent mechanism. The SGLT2 is a
transporter found in the kidney proximal tubule and is responsible for approximately 90% of
renal glucose reabsorption. The SGLT2 inhibitors like dapagliflozin are highly selective
SLGT2-inhibitors and reduce reabsorption of glucose in the kidney. As a consequence,
glucose excretion increases in the urine, resulting in glycouria, whereas plasma glucose levels
decrease in blood, an insulin independent reduction. Thus, SGLT-2 inhibitors do not confer
any risk of hypoglycemia. In addition to improvements in glycemic control, dapagliflozin
therapy is also associated with a beneficial reduction in total body weight. A disadvantage for
SGLT-2 inhibitors is an increased incidence of genital infections.
Alpha-glucosidase inhibitors (AGIs): AGIs such as acarbose, voglibose and miglitol are
pseudo-carbohydrates that competitively inhibit α-glucosidase enzymes located in the brush
border of small intestine that hydrolyze non-absorbable polysaccharides and oligosaccharides
into absorbable monosaccharides. As a result, the effect of these drugs is to retard glucose
absorption after a meal, and consequently lowers postprandial insulin levels and
hyperglycemia peaks in patients with few β-cell reserves. AGIs are commonly used to control
postprandial blood glucose and to reduce the insulin requirement without causing
hypoglycemia and weight gain. AGIs can be administered as monotherapy or in combination
with any other blood glucose-lowering drug, including insulin for the treatment of T2DM.
The primary drawback of α-glucosidase inhibitors is its gastrointestinal disturbance such as
flatulence and diarrhea.
Strategies for insulin therapy: Insulin therapy was classically considered a last step for
T2DM patients and did not use until all other treatments failed. The goals of insulin therapy
in T2DM are glycemic and metabolic control to prevent micro- and macrovascular
complications. People should be aware if the insulin dose is too high or incorrectly
distributed, hypoglycemia and marked weight gain may occur. The treatment begins at a dose
of 10 to 20 IU of a long-acting insulin preparation. Depending on the patient’s weight, a dose
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
346
increase by 2 IU every three days may be required until the morning glucose values are
within the target range. If glycemic peaks after meals are the main problem, then insulin
therapy would more reasonably be initiated with insulin administration only at mealtimes. It
is increasingly being recognized that insulin may be used at an early stage of T2DM. Recent
treatment guidelines recommend the use of insulin, especially basal insulin, as part of an
early treatment regimen in the disease process. The early insulin therapy may slow or even
halt diabetes progression. In patients with newly diagnosed T2DM, several small-scale
studies have demonstrated that short term intensive insulin treatment can induce disease
remission (defined by normal glucose levels) for up to 2 years. The ADA and EASD
recommend starting insulin treatment with basal insulin based on both the efficacy and
relative safety of this approach. Currently available basal insulin analogs, such as insulin
glargine (Lantus; Sanofi, Paris, France) and insulin detemir (Levemir; Novo Nordisk Inc,
Plainsboro, NJ) offer better improvement in terms of duration of action and reduced peak
effect.
Bariatric surgery: Bariatric surgery includes Roux-en-Y gastric bypass (RYGB),
laparoscopic sleeve gastrectomy (LSG), laparoscopic adjustable gastric banding (LAGB),
biliopancreatic diversion (BPD) and the biliopancreatic diversion with a duodenal switch
(BPD-DS). The RYGB and the BPD procedures bypass a full length of normal intestine
(bypass procedures) whereas the LAGB and LSG only restrict the normal flow of food
(restrictive procedures). Most T2DM patients are overweight or obese. Patients with T2DM
and body mass index (BMI) 35 kg/m2 are currently eligible for bariatric surgery, according to
the NIH Consensus Criteria for bariatric surgery. Recent meta-analyses of 16 studies with
6131 patients and mean 17.3-month follow-up have found bariatric surgery to be superior to
conventional medical therapy in achieving significant weight loss, HbA1c and fasting plasma
glucose reduction and diabetes remission. Thus, bariatric surgery has been accepted as the
most effective treatment along with significant metabolic benefits for patients with T2DM
and BMI >35 kg/ m2. Weight loss after surgery is not due to intestinal malabsorption, but due
to decreased food consumption from decreased appetite. Evidence exists that changes in the
gut hormonal milieu after gastric bypass can improve insulin resistance immediately after
surgery and proceed substantial weight loss.
Chinese herbal medicines: As mentioned above, a number of anti-diabetic drugs are
effective for T2DM treatment. However, these medications frequently have side effects, such
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
347
as weight gain, bone loss, and increased risk of cardiovascular events. These side effects
could become more prevalent due to continuous treatment of chronic diseases. Herbal
medications can be a good alternative in combination with or as a partial replacement for
Western medications. Because herbal medicines are usually derived from natural plants, they
are considered to be relatively safe and have fewer side effects compared to the conventional
drugs. Herbal medicine has long been used in China in the treatment of diabetes for several
thousands of years and currently it has been intensively used for diabetes treatment. Over
70% of Chinese patients are treated with traditional Chinese herbal medicines. Diabetes is a
huge burden in China, where approximately 100 million people have been diagnosed with the
disease and the prevalence is 9.7% in China. The application of herbal medicines for diabetic
patients is increasing in clinics across the United States. Investigation shows that among
people with diabetes, 22.3% of patients use herbal therapy or folk medicine. It is estimated
that more than 200 species of plants exhibit hypoglycaemic properties. The investigation
shows that about 33 Chinese traditional medicines such as Radix Astragali seu Hedysari,
Radix Rehmanniae and Radix Rehmanniae, Praeparata, Radix Trichosanthis, are most
frequently used in Chinese traditional prescriptions for the clinical treatment of diabetes and
its complications. Some Chinese anti-diabetic herbs have been proven effective although
some research findings are not consistent. Clinical evidence and animal tests show that many
Chinese herbs are beneficial in lowering blood glucose and increase insulin sensitivity.
Mechanism and philosophy of Chinese herbal medicines and Western medicine are different.
CONCLUSION
The past decades have witnessed a rapid rise in the prevalence of diabetes, especially in the
urban areas. The fact that there is a shift in age of onset to younger age groups is alarming as
this could have adverse effects on the nation’s economy. Hence, the early identification of at
risk individuals and appropriate intervention in the form of weight reduction, changes in
dietary habits and increased physical activity could greatly help to prevent, or at least delay,
the onset of diabetes and thus reduce the burden due to non communicable diseases in India.
We describe the current understanding of T2DM diagnostic criteria and antidiabetic
medications including Chinese herbs. We highlight some issues that should be addressed for
clinicians and patients. Although T2DM diagnosis and treatment have been improved in the
past decade, current available medicines are not able to completely curb the development of
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
348
T2DM and its complications. Thus, it is important to develop new drugs with improved
safety and efficacy for treatment of T2DM in the future.
REFERENCES
1. Huizinga MM, Rothman RL. Addressing the diabetes pandemic: A comprehensive
approach. Indian J Med Res, 2006; 124: 481-4.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates
for the year 2000 and projections for 2030. Diabetes Care, 2004; 27: 1047-53.
3. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor.
Diabetes Atlas. International Diabetes Federation. 3rd ed. Belgium: International Diabetes
Federation, 2006; 15-103.
4. Ahuja MMS. Epidemiological studies on diabetes mellitus in India. In: Ahuja MMS,
editor. Epidemiology of diabetes in developing countries. New Delhi: Interprint, 1979;
29-38.
5. Ramachandran A, Jali MV, Mohan V, Snehalatha C, Viswanathan M. High prevalence of
diabetes in an urban population in south India. BMJ, 1988; 297: 587-90.
6. Sridhar GR, Rao PV, Ahuja MMS. Epidemiology of diabetes and its complications. In:
RSSDI textbook of diabetes mellitus. Hyderabad: Research Society for the Study of
Diabetes in India, 2002; 95-112.
7. Rao PV, Ushabala P, Seshaiah V, Ahuja MMS, Mather HM. The Eluru survey:
prevalence of known diabetes in a rural Indian population. Diabetes Res Clin Pract, 1989;
7: 29-31.
8. Ramachandran A, Snehalatha C, Dharmaraj D, Viswanathan M. Prevalence of glucose
intolerance in Asian Indians. Urban-rural difference and significance of upper body
adiposity. Diabetes Care, 1992; 15: 1348-55.
9. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M. Rising prevalence of
NIDDM in an urban population in India. Diabetologia, 1997; 40: 232-7.
10. Raman Kutty V, Joseph A, Soman CR. High prevalence of type 2 diabetes in an urban
settlement in Kerala, India. Ethn Health, 1999; 4: 231-9.
11. Shah SK, Saikia M, Burman NN, Snehalatha C, Ramachandran A. High prevalence of
type 2 diabetes in urban population in north eastern India. Int J Diabetes Dev Countries,
1999; 19: 144-7.
www.wjpr.net Vol 9, Issue 5, 2020.
Dinesh et al. World Journal of Pharmaceutical Research
349
12. Zargar AH, Khan AK, Masoodi SR, Laway BA, Wani AI, Bashir MI, et al. Prevalence of
type 2 diabetes mellitus and impaired glucose tolerance in the Kashmir Valley of the
Indian subcontinent. Diabetes Res Clin Pract, 2000; 47: 135-6.
13. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. Diabetes
Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired
glucose tolerance in India: National Urban Diabetes Survey. Diabetologia, 2001; 44:
1094-101.
14. Alberti KG, Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and
its complications. Part I: Diagnosis and classification of diabetes mellitus, provisional
report of a WHO consultation. Diabetes Med, 1998; 15: 539-53.
15. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes,
impaired fasting glucose and insulin resistance syndrome in an urban Indian population.
Diabetes Res Clin Pract, 2003; 61: 69-76.
16. Deo SS, Zantye A, Mokal R, Mithbawkar S, Rane S, Thakur K. To identify the risk
factors for high prevalence of diabetes and impaired glucose tolerance in Indian rural
population. Int J Diab Dev Ctries, 2006; 26: 19-23.
17. Menon VU, Kumar KV, Gilchrist A, Sugathan TN, Sundaram KR, Nair V, et al.
Prevalence of known and undetected diabetes and associated risk factors in central Kerala
- ADEPS. Diabetes Res Clin Pract, 2006; 74: 289-94.
18. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S, et al. The Chennai
Urban Rural Epidemiology Study (CURES) - study design and methodology (urban
component) (CURES-I). J Assoc Physicians India, 2003; 51: 863-70.
19. Mohan V, Deepa M, Deepa R, Shantirani CS, Farooq S, Ganesan A, et al. Secular trends
in the prevalence of diabetes and glucose tolerance in urban South India - the Chennai
Urban Rural Epidemiology Study (CURES-17). Diabetologia, 2006; 49: 1175-8.
20. Misra A, Vikram NK, Arya S, Pandey RM, Dhingra V, Chatterjee A, et al. High
prevalence of insulin resistance in post-pubertal Asian Indian children is associated with
adverse truncal body fat patterning, abdominal adiposity and excess body fat. Int J Obes
Relat Metab Disord, 2004; 28: 1217-26.
21. Kutty VR, Soman CR, Joseph A, Pisharody R, Vijayakumar K. Type 2 diabetes in
southern Kerala. Variation in prevalence among geographic divisions within a region.
Natl Med J India, 2000; 13: 287-92.